Literature DB >> 10607712

Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma.

E M Boneberg1, L Hareng, F Gantner, A Wendel, T Hartung.   

Abstract

In a double-blind, placebo-controlled, randomized study, 10 healthy men received either a single dose of 480 microg granulocyte colony-stimulating factor (G-CSF) or saline. Blood taken from the volunteers was stimulated with 10 microg/mL endotoxin and released cytokines were measured by enzyme-linked immunosorbent assay. Expression of G-CSF receptors on leukocytes was examined by flow cytometry and reverse transcriptase-polymerase chain reaction. Functional activity of these receptors was tested by challenging isolated leukocyte populations to release cytokines with endotoxin in the presence of G-CSF. The G-CSF treatment attenuated the release of the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin (IL)-12, IL-1beta, and interferon (IFN)-gamma in ex vivo lipopolysaccharide (LPS)-stimulated whole blood. In blood from untreated volunteers the presence of G-CSF in vitro also attenuated the LPS-stimulated release of these cytokines. G-CSF in vitro also attenuated TNF-alpha release from elutriation-purified monocytes. In the presence of 10 ng/mL recombinant TNF-alpha, the attenuation of LPS-inducible IFN-gamma release by G-CSF was blunted in whole blood. However, G-CSF had no such effect on IFN-gamma release from isolated lymphocytes stimulated with anti-CD3 or a combination of TNF-alpha and IL-12. G-CSF receptor expression was detected in human neutrophils and monocytes but not in lymphocytes by means of RT-PCR as well as flow cytometry. These results indicate that G-CSF receptors expressed on monocytes are functional in modulating monokine release. We conclude that the attenuation of IFN-gamma release from lymphocytes is not a direct effect of G-CSF on these cells but is rather due to the inhibition of monocytic IL-12 and TNF-alpha release by G-CSF. (Blood. 2000;95:270-276)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607712

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Recombinant filgrastim (BK0023) pharmacodynamics and pharmacokinetics after single and multiple escalating doses in an equivalence study in healthy men.

Authors:  Andrea F D Di Stefano; Gaia Spinetti; Antonio Rusca; Milko M Radicioni; Luca Loprete; Domenica M G Lamparelli; Jutta Michael Hepp; Davide Crobu; Rodolfo Schrepfer; Giancarlo Tonon
Journal:  Clin Drug Investig       Date:  2015-09       Impact factor: 2.859

2.  Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100.

Authors:  Rebecca M Shepherd; Benjamin J Capoccia; Steven M Devine; John Dipersio; Kathryn M Trinkaus; David Ingram; Daniel C Link
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 3.  Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction.

Authors:  Hiroyuki Takano; Yingjie Qin; Hiroshi Hasegawa; Kazutaka Ueda; Yuriko Niitsuma; Masashi Ohtsuka; Issei Komuro
Journal:  J Mol Med (Berl)       Date:  2006-01-17       Impact factor: 4.599

Review 4.  The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis.

Authors:  Andrew Martins; Jiahuai Han; Sung O Kim
Journal:  IUBMB Life       Date:  2010-08       Impact factor: 3.885

5.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

Review 6.  Effects and safety of granulocyte colony-stimulating factor in healthy volunteers.

Authors:  Paolo Anderlini
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

7.  Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naïve T cells.

Authors:  Maura Rossetti; Silvia Gregori; Maria Grazia Roncarolo
Journal:  Eur J Immunol       Date:  2010-10-19       Impact factor: 5.532

8.  Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.

Authors:  P J Mannon; F Leon; I J Fuss; B A Walter; M Begnami; M Quezado; Z Yang; C Yi; C Groden; J Friend; R L Hornung; M Brown; S Gurprasad; B Kelsall; W Strober
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

9.  Granulocyte colony-stimulating factor (G-CSF) protects oligodendrocyte and promotes hindlimb functional recovery after spinal cord injury in rats.

Authors:  Ryo Kadota; Masao Koda; Junko Kawabe; Masayuki Hashimoto; Yutaka Nishio; Chikato Mannoji; Tomohiro Miyashita; Takeo Furuya; Akihiko Okawa; Kazuhisa Takahashi; Masashi Yamazaki
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

10.  Hochuekkito, a Kampo (Traditional Japanese Herbal) Medicine, and its Polysaccharide Portion Stimulate G-CSF Secretion from Intestinal Epithelial Cells.

Authors:  Tsukasa Matsumoto; Michiyo Moriya; Hiroaki Kiyohara; Yoshiaki Tabuchi; Haruki Yamada
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.